Brief: Ryvu Therapeutics Says FDA Lifts Partial Clinical Hold On Rvu120 Phase Ib Study In Acute Myeloid Leukemia And Myelodysplastic Syndrome
14/07/2021 13:40
July 14 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* FDA LIFTS PARTIAL CLINICAL HOLD ON RVU120 (SEL120) PHASE
IB
STUDY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
Source text for Eikon: ID:nEM4kRkVpa
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project